Limits...
Localized Surface Plasmon Resonance Biosensing: Current Challenges and Approaches.

Unser S, Bruzas I, He J, Sagle L - Sensors (Basel) (2015)

Bottom Line: In this article, we have categorized these challenges into four categories: improving sensitivity and limit of detection, selectivity in complex biological solutions, sensitive detection of membrane-associated species, and the adaptation of sensing elements for point-of-care diagnostic devices.The following section will describe various LSPR platforms designed for the sensitive detection of membrane-associated species.Finally, recent advances towards multiplexed and microfluidic LSPR-based devices for inexpensive, rapid, point-of-care diagnostics will be discussed.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemistry, College of Arts and Sciences, University of Cincinnati, 301 West Clifton Court, Cincinnati, OH 45221-0172, USA. unsersa@mail.uc.edu.

ABSTRACT
Localized surface plasmon resonance (LSPR) has emerged as a leader among label-free biosensing techniques in that it offers sensitive, robust, and facile detection. Traditional LSPR-based biosensing utilizes the sensitivity of the plasmon frequency to changes in local index of refraction at the nanoparticle surface. Although surface plasmon resonance technologies are now widely used to measure biomolecular interactions, several challenges remain. In this article, we have categorized these challenges into four categories: improving sensitivity and limit of detection, selectivity in complex biological solutions, sensitive detection of membrane-associated species, and the adaptation of sensing elements for point-of-care diagnostic devices. The first section of this article will involve a conceptual discussion of surface plasmon resonance and the factors affecting changes in optical signal detected. The following sections will discuss applications of LSPR biosensing with an emphasis on recent advances and approaches to overcome the four limitations mentioned above. First, improvements in limit of detection through various amplification strategies will be highlighted. The second section will involve advances to improve selectivity in complex media through self-assembled monolayers, "plasmon ruler" devices involving plasmonic coupling, and shape complementarity on the nanoparticle surface. The following section will describe various LSPR platforms designed for the sensitive detection of membrane-associated species. Finally, recent advances towards multiplexed and microfluidic LSPR-based devices for inexpensive, rapid, point-of-care diagnostics will be discussed.

No MeSH data available.


(a) An HIV detection assay is depicted which relies on carbodiimide chemistry to cover the surface with antibodies specific for HIV subtypes; (b) The plasmonic system can detect and distinguish between HIV subtypes A, B, C, D, E, G in patients with HIV [136].
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4541850&req=5

sensors-15-15684-f006: (a) An HIV detection assay is depicted which relies on carbodiimide chemistry to cover the surface with antibodies specific for HIV subtypes; (b) The plasmonic system can detect and distinguish between HIV subtypes A, B, C, D, E, G in patients with HIV [136].

Mentions: An initial application of LSPR biosensing platforms for clinical use was carried out by Haes et al. in 2005 and detected a biomarker, amyloid-derived diffusible ligand (ADDL), for Alzheimer’s disease [131]. An array of 90 nm silver nanoprisms was fabricated using nanosphere lithography [25], which were functionalized with anti-ADDLs and exposed to varying concentrations of ADDLs. After this, additional anti-ADDLs were added to boost the detected signal. This was then successfully tested in cerebrospinal fluid from Alzheimers patients. Since then, many plasmonic sensors have been developed for potential POC use for various diseases. One disease that disproportionately affects developing countries is HIV, thus many LSPR platforms have been developed towards the detection of the HIV virus or HIV-associated proteins and DNA [132,133,134,135,136]. A recent study by Demirci et al. accurately captured, detected, and quantified different subtypes (A, B, C, D, E, and G subtype panel) of HIV with accuracy of 98 ± 39 copies/mL for Virus subtype D. Tests were conducted in whole blood samples from HIV patients on a gold platform using immunochemistry to trap the virus particles monitoring wavelength shifts with high reproducibility, sensitivity and specificity, see Figure 6 [136]. In addition to HIV, other point-of-care plasmonic detection schemes have been developed to detect viruses [137,138,139,140] and cancer [141,142,143] in resource limited environments.


Localized Surface Plasmon Resonance Biosensing: Current Challenges and Approaches.

Unser S, Bruzas I, He J, Sagle L - Sensors (Basel) (2015)

(a) An HIV detection assay is depicted which relies on carbodiimide chemistry to cover the surface with antibodies specific for HIV subtypes; (b) The plasmonic system can detect and distinguish between HIV subtypes A, B, C, D, E, G in patients with HIV [136].
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4541850&req=5

sensors-15-15684-f006: (a) An HIV detection assay is depicted which relies on carbodiimide chemistry to cover the surface with antibodies specific for HIV subtypes; (b) The plasmonic system can detect and distinguish between HIV subtypes A, B, C, D, E, G in patients with HIV [136].
Mentions: An initial application of LSPR biosensing platforms for clinical use was carried out by Haes et al. in 2005 and detected a biomarker, amyloid-derived diffusible ligand (ADDL), for Alzheimer’s disease [131]. An array of 90 nm silver nanoprisms was fabricated using nanosphere lithography [25], which were functionalized with anti-ADDLs and exposed to varying concentrations of ADDLs. After this, additional anti-ADDLs were added to boost the detected signal. This was then successfully tested in cerebrospinal fluid from Alzheimers patients. Since then, many plasmonic sensors have been developed for potential POC use for various diseases. One disease that disproportionately affects developing countries is HIV, thus many LSPR platforms have been developed towards the detection of the HIV virus or HIV-associated proteins and DNA [132,133,134,135,136]. A recent study by Demirci et al. accurately captured, detected, and quantified different subtypes (A, B, C, D, E, and G subtype panel) of HIV with accuracy of 98 ± 39 copies/mL for Virus subtype D. Tests were conducted in whole blood samples from HIV patients on a gold platform using immunochemistry to trap the virus particles monitoring wavelength shifts with high reproducibility, sensitivity and specificity, see Figure 6 [136]. In addition to HIV, other point-of-care plasmonic detection schemes have been developed to detect viruses [137,138,139,140] and cancer [141,142,143] in resource limited environments.

Bottom Line: In this article, we have categorized these challenges into four categories: improving sensitivity and limit of detection, selectivity in complex biological solutions, sensitive detection of membrane-associated species, and the adaptation of sensing elements for point-of-care diagnostic devices.The following section will describe various LSPR platforms designed for the sensitive detection of membrane-associated species.Finally, recent advances towards multiplexed and microfluidic LSPR-based devices for inexpensive, rapid, point-of-care diagnostics will be discussed.

View Article: PubMed Central - PubMed

Affiliation: Department of Chemistry, College of Arts and Sciences, University of Cincinnati, 301 West Clifton Court, Cincinnati, OH 45221-0172, USA. unsersa@mail.uc.edu.

ABSTRACT
Localized surface plasmon resonance (LSPR) has emerged as a leader among label-free biosensing techniques in that it offers sensitive, robust, and facile detection. Traditional LSPR-based biosensing utilizes the sensitivity of the plasmon frequency to changes in local index of refraction at the nanoparticle surface. Although surface plasmon resonance technologies are now widely used to measure biomolecular interactions, several challenges remain. In this article, we have categorized these challenges into four categories: improving sensitivity and limit of detection, selectivity in complex biological solutions, sensitive detection of membrane-associated species, and the adaptation of sensing elements for point-of-care diagnostic devices. The first section of this article will involve a conceptual discussion of surface plasmon resonance and the factors affecting changes in optical signal detected. The following sections will discuss applications of LSPR biosensing with an emphasis on recent advances and approaches to overcome the four limitations mentioned above. First, improvements in limit of detection through various amplification strategies will be highlighted. The second section will involve advances to improve selectivity in complex media through self-assembled monolayers, "plasmon ruler" devices involving plasmonic coupling, and shape complementarity on the nanoparticle surface. The following section will describe various LSPR platforms designed for the sensitive detection of membrane-associated species. Finally, recent advances towards multiplexed and microfluidic LSPR-based devices for inexpensive, rapid, point-of-care diagnostics will be discussed.

No MeSH data available.